BI-0474 is a covalent KRASG12C inhibitor. The IC50 value for GDP-KRAS::SOS1 protein-protein interaction was 7.0 nM. BI-0474 also showed better antitumor activity in non-small cell lung cancer xenograft models.
Powder -20°C 3 years ; 4°C 2 years
In solvent -80°C 6 months ; -20°C 1 month
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
|Related Ras Products|
BI 1823911 is a novel, highly selective, covalently irreversible oral small molecule inhibitor of KRASG12C.
ARS-3248 is a novel KRAS G12C inhibitor.
LY3499446 is a KRAS G12C covalent inhibitor for studies related to non-small cell lung cancer (NSCLC).
ACBI3 is a selective and potent pan-KRAS degrader.
MK-1084 is a KRAS G12C inhibitor that can be used in studies related to solid tumors.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.